Printer Friendly

First Insight into the Molecular Epidemiology of Mycobacterium tuberculosis Isolates from the Minority Enclaves of Southwestern China.

1. Introduction

Tuberculosis (TB), caused by Mycobacterium tuberculosis complex (MTBC), remains a major global health concern and ranks as the second leading cause of death from infectious diseases [1]. The World Health Organization (WHO) estimates that TB caused 9.6 million new cases and 1.5 million deaths in 2014 [2]. Only behind India and Indonesia, China has the world's third-largest amount of TB patients, with an approximately 1.0 million new cases reported annually [2]. According to the most recent national TB epidemiological survey, the prevalence of pulmonary TB was 442 cases per 100,000 population in China [3]. Despite the decreased trend in the incidence and mortality rate from 1990 to 2010, TB is still one of the most important issues threatening the public health and social development in China [3, 4].

Molecular epidemiological investigation has been proved to be a useful tool for TB control and surveillance, which allows us to better understand the dynamic of disease transmission and distinguish between relapse and infection [5]. In addition, there is increasing evidence that certain genotypes of M. tuberculosis are associated with drug resistance, virulence, and disease progression [6]. Hence, the knowledge regarding strain diversity within the patients has special contemplation during TB epidemics or suspected outbreaks, thereby providing new insights for establishing strategic measures for TB control and prevention [7, 8].

Yunnan is located in southwestern China, with an area of 394,100 square kilometers and a population of 46.9 million people in 2013. Out of all inhabitants, there are remarkable 14.0 million inhabitants belonging to 55 different ethnic minority groups, accounting for one-third of the whole inhabitants. In addition, most of these minority inhabitants live along the border with Myanmar, Laos, and Vietnam. According to the data from provincial surveillance system for TB, the overall incidence of pulmonary TB was 56 cases per 100,000 population in Yunnan [9]. The diversity of TB burden was also observed across the different regions, and the TB incidences in several regions of ethnic enclaves were three times higher than the average incidence [9]. Therefore, it is meaningful to investigate the patient's structure and drug susceptibility of MTB isolates circulating in Yunnan Province to highlight the geographic diversity of TB in ethnic enclaves. Unfortunately, limited data have been reported on this issue. In this study, our aim was to characterize the genotypes of MTB strains collected in Yunnan and to investigate the transmission profile of the predominant TB genotypes in this area.

2. Materials and Methods

2.1. Ethics Statement. This study was approved by the Ethics Committee of the Yunnan Provincial Center for Disease Control and Prevention. Patients were enrolled in the study after agreeing to and signing an Informed Consent form.

2.2. Bacterial Isolates. All smear-positive pulmonary TB patients seeking health care at six prefectural TB dispensaries in 2014 were continuously enrolled in this study, including Qujing, Lijiang, Dehong, Lincang, Puer, and Xishuangbanna. Demographic information was collected from Informed Consent forms. Two sputum samples from each patient were used for mycobacteria culturing with Lowenstein-Jensen (L-J) medium. One strain from each patient was collected for further molecular epidemiological study.

2.3. DNA Extraction. The crude genomic DNA of MTB isolates were extracted as previously reported [5]. Briefly, a loopful of colonies from L-J slants were transferred to a microcentrifuge tube containing 500 [micro]L Tris-EDTA (TE) buffer. Followed by heating at 95[degrees]C water bath for 30 min, the suspension was centrifuged at 12000 rpm for 10 min. The DNA in the supernatant was pipetted into a microcentrifuge tube for further PCR amplification.

2.4. Drug Susceptibility Testing (DST). The proportional method was performed to determine the in vitro drug susceptibility of MTB isolates against isoniazid (INH) and rifampicin (RFP) according to the recommendations by the World Health Organization [4, 9]. The concentrations of INH and RFP in the L-J medium were 0.2 [micro]g/mL and 40 [micro]g/mL, respectively. The resistance of a strain against a drug was declared when the growth rate was higher than 1% compared with the control. The Yunnan Provincial TB Reference Laboratory has passed the DST proficiency tests of the National TB Reference Laboratory since 2007. Multiple drug resistant tuberculosis (MDR-TB) isolates were defined as strains being resistant to both INH and RFP.

2.5. Genotyping. Spoligotyping was performed using commercial kit manufactured by Isogen Bioscience BV (Maarssen, Netherlands) [4]. The genomic DNA was amplified with primers DRa (5,-CCGAGAGGGGACGGAAAC-3,) and DRb (5'-GGTTTTGGGTCTGACGAC-3'). The amplicons were hybridized with a membrane and the final image was detected with a chemiluminescence system (Amersham, Buckinghamshire, United Kingdom). The original binary data were entered in the SITVITWEB database to obtain the Spoligotyping International Type (SIT) patterns and the sublineages of MTB isolates [10]. In addition, all the isolates were genotyped with the 12-locus VNTR set with high discriminatory power described by Luo et al. [11]. The PCR products were analyzed using 1.5% agarose electrophoresis at 5 V/cm for 1 hour. The 100 bp DNA ladder and amplicons of H37Rv were loaded per 7 lanes as a size marker to calculate the repeat number of each locus. The Hunter-Gaston Discriminatory Index (HGDI) was used to analyze the discriminatory power of each VNTR locus [12]. In addition, the genotyping patterns were clustered with BioNumerics software version 5.0 (Applied Maths, Sint-Martens-Latem, Belgium).

2.6. Data Analysis. A chi-square test was performed to detect any significant difference between the two groups, and the statistical results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Two-sided P value of <0.05 was declared as statistically significant. All calculations were analyzed in SPSS 14.0 (SPSS Inc., USA).

3. Results

3.1. Drug Susceptibility Profiles and Demographic Characteristics of Han and Minority Patients. A total of 271 MTB isolates represented patients from different districts across Yunnan Province (Figure 1). Out of these patients, 196 (72.3%) were males, and 75 were females. The mean age of the patients was 49.8 [+ or -] 12.1 years (range: 16-76 years). In addition, all the 271 patients were classified as 11 different ethnic groups, including 133 Han patients (49.1%) and 138 minority patients (50.9%). Of these minority groups, Hani, Yi, and Dai were the most frequently observed, accounting for 11.1% (30/271), 10.3% (28/271), and 9.6% (26/271) of all the patients, respectively. We further analyzed the distribution of demographic and drug susceptibility characteristics between Han and minority patients. As shown in Table 1, statistical analysis indicated that the proportion of minority patients in Qujing (2.0%, 1/49) were significantly lower than that in Puer (71.3%, 67/94), Xishuangbanna (70.0%, 28/40), Lijiang (63.6%, 14/22), Dehong (62.8%, 2/35), and Lincang (19.4%, 6/31), respectively (P < 0.05). Compared with Han patients, the minority patients had higher proportion of farmers (88.4% versus 78.2%, P = 0.02). In addition, we found that the Han patients were significantly associated with RIF resistance (P = 0.03), while the rate of INH resistance showed no statistically significant difference. Although all the MDRTB patients belonged to Han patients, the difference in the prevalence of MDR-TB between Han and minority patients was not significant (Table 3), which was more likely to be attributed to small sample size. Demographic characteristics, including gender, age, and treatment history, showed no statistical difference between Han and minority patients.

3.2. Spoligotyping. The 271 MTB isolates were analyzed by spoligotyping in this study. The 271 genotyped strains were divided into 16 types shared by 2 to 136 isolates and 24 orphans (genotypes found only once in study). Out of these spoligotypes, SIT1 was the largest lineage (50.2%, 136/271), which belonged to the classical Beijing genotype. In addition, the second largest type was SIT53 from T1 family that included 35 isolates (12.9%, Table 2). Eleven types, containing 21 isolates, were identified for the first time.

Based on spoligotyping, 151 (55.7%) MTB strains belonged to the Beijing genotype, while the other 120 (44.3%) were from non-Beijing families, indicating that Beijing genotype was the predominant sublineage in Yunnan. Strains assigned to non-Beijing family included 45 from T1 family (16.6%), 34 from T3 family (12.5%), 6 from LAM9 family (2.2%), 5 from the T2 family (1.8%), 4 from T2-T3 family (1.5%), 2 from MANU2 family (0.7%), 1 from T5 family (0.4%), 1 from H3 family (0.4%), 1 from X2 family (0.4%), and 21 of undefined genotypes (7.7%, Table 2).

3.3. Drug Susceptibility Profiles and Demographic Characteristics of Beijing and Non-Beijing MTB Isolates. We compared the proportion of drug susceptibility profiles and demographic characteristics of patients identified as infection with Beijing and non-Beijing genotypes. Statistical analysis indicated that the distribution of Beijing genotype showed geographic diversity, and the proportion of Beijing genotype in Qujing was significantly higher than that in the ethnic enclaves (P [less than or equal to] 0.01). Compared with the percentage of Beijing-family isolates from patients under age of 25 years, those from patients aged 45~64 years [OR (95% CI): 0.30 (0.14~0.66), P < 0.01] and older than 64 years [OR (95% CI): 0.35 (0.13~0.95), P = 0.04] were significantly lower. With regard to the gender distribution of Beijing genotype strains, the percentage of female patients infected with Beijing genotype strains was significantly higher than that of male patients, indicating that women might be at high risk for the infection of Beijing genotype strains [OR (95% CI): 2.04 (1.17~3.57), P = 0.01]. Our data revealed that occupation, treatment history, and drug resistance showed no statistically significant association with the Beijing genotype (Figure 1 and Table 3).

3.4. VNTR. Using the 12-locus high-resolution VNTR method, the 271 isolates were differentiated into 30 clusters (2 to 17 isolates per cluster) and 177 unique genotypes, showing a clustering rate of 23.6% (Figure 2 and Table S1 in Supplementary Material available online at https://doi.org/10.1155/ 2017/2505172). We also analyzed the clustering rate according to different patients. Our data revealed that the clustering rate of Han patients (26.3%, 35/133) was significantly higher than that of minority patients (15.2%, 21/138, P = 0.024). In addition, Beijing genotype strains (23.8%, 36/151) showed higher clustering rate than non-Beijing genotype strains (16/120, 13.3%, P = 0.029). Interestingly, the largest cluster with 6 3 8 2 4 8 5 3 3 8 4 2 VNTR profile contained 17 strains, which were all from Han patients in Qujing district. As shown in Table 4, eight out of the 12 VNTR loci, including Qub11b, Qub18, Qub26, MIRU26, Mtub21, Mtub04, ETRF, and MIRU31, were highly discriminating loci, the allelic diversity for which was higher than 0.6 [13]. All the other 4 loci (MIRU10, Qub4156, MIRU40, and Qub1895) showed moderate discrimination (0.3 [less than or equal to] HGDI [less than or equal to] 0.6). In addition, we found that the loci exhibited different discriminating ability to distinguish Beijing and non-Beijing genotype strains. Qub26, Mtub04, and MIRU40 showed higher discriminating power for non-Beijing genotype strains, while Mtub21 and Qub4156 were more effective in identifying Beijing genotype strains (Table 4).

4. Discussion

This study provides the first insight into the molecular epidemiological characteristics of MTB strains circulating in Yunnan Province, China. Our data revealed that Beijing genotype is still the predominant genotype throughout Yunnan, accounting for 55.7% of the MTB strains in the present study. The prevalence of Beijing genotype is similar to that in Fujian (57.3%) [14] and that in Guangxi (61.9%) [15], although it is lower than most regions in China, ranging from 76.7% to 91.9% [16-19]. All these findings were consistent with a recent study by Pang et al. (2012) [4], which revealed that the distribution of Beijing differed from one geographic region to another in China, and the Beijing genotype constitutes 76.5% of the MTB strains currently epidemic in north China, with only 53.2% of those in south China. Although the exact reason for the relative low prevalence of Beijing genotypes in south China remains elusive, it is believed to be associated with the natural environment, living habit, and the evolution history of Beijing genotype [4, 20].

In addition, we also found that the distribution of Beijing genotype showed remarkable geographic diversity in Yunnan, which may be attributed to the different composition of minority patients among these regions. The prevalence of Beijing genotype in the Han enclaves was significantly higher than that in the minority enclaves, which was consistent with the observation from Luo and colleagues [20]. In Yunnan, as opposed to Han patients, the minority patients generally live in the mountainous areas located in the national boundary lines rather than the plain areas. Hence, the lower patient densities of mountainous areas may play an important role in decreasing the transmission of the epidemic Beijing lineage. In addition, due to living in the regions bordering Vietnam and Myanmar, the minority patients prefer to move across national boundary lines for commercial trade. Considering the frequent patient communication between minority patients and neighboring foreigner, the relatively low prevalence of Beijing genotype in Vietnam (35%) [21] and Myanmar (32%) [22] may be another potential reason responsible for our findings.

Several previous studies demonstrated that the Beijing genotype is associated with young patients (aged less than 25 years) [21, 23], while researchers from other countries observed no association between the infection with the Beijing genotype and a patient age [24]. In line with the former results, we also found that young age was a risk factor for the infection with Beijing genotype strain. On one hand, compared with the older patients, children and young adults undergo higher level of social activities [25]. In view of the increased transmissibility of Beijing genotype [26], the more frequent social interactions may cause the recent transmission of Beijing strains in these patients. On the other hand, BCG vaccination was included in the National Immunization Program of China since 1980s [27]. Previous studies have hypothesized that Beijing strains could escape from insufficient protection induced by BCG [28, 29], which may be responsible for their emergence in the BCG-vaccinated young patients. In addition to age, we observed that infection with Beijing genotype was associated with gender, while the exact reason for this difference still remains unknown.

A recent report from Yang and colleagues (2015) has demonstrated that Beijing genotype strains favor transmission in China [26], which is consistent with our observation that the rate of Beijing genotype was significantly higher than that of non-Beijing genotype. Considering the lower prevalence of Beijing genotype strains in the minority patients, it also serves as the dominant contributor to the lower clustering rate of TB strains in these patients. Interestingly, we also identified a suspected outbreak in Qujing of Yunnan Province, which included 17 Beijing genotype strains sharing the same VNTR pattern. Further epidemiological investigation will help us to identify the "superspreader" of this outbreak. Recently, numerous studies have declared that VNTR can not capture the full level of genetic diversity within a single MTB genotype, while Whole-Genome Sequencing (WGS) serves as a useful tool to identify MTB isolates associated with tuberculosis outbreak due to its inherent advantages exceeding conventional molecular epidemiologic techniques [30, 31]. Nevertheless, our genotyping data using VNTR reflect the potential ongoing community transmission in Yunnan, which highlights the urgent need for early diagnosis of the infectious TB cases to avoid a large TB outbreak. In recent years, more than 70% of TB laboratories in Yunnan have been equipped with the molecular diagnosis tools, including GeneXpert and LAMP, and further the application of molecular techniques with high sensitivity for TB diagnosis will increase access to testing and decrease diagnostic delays in a resource-limited county, thereby decreasing the transmission of TB in the community.

In conclusion, our data demonstrated that the Beijing genotype was the predominant MTB genotype in Yunnan Province. The prevalence of Beijing genotype strains in the Han enclaves was significantly higher than that in the minority enclaves, indicating that distribution of TB strain showed geographic diversity. In addition, we observed that Beijing genotype was more likely to contribute to recent transmission rather than drug resistance. The suspected TB outbreak identified by VNTR highlights the urgent need for early diagnosis of the infectious TB cases to avoid a large TB outbreak.

https://doi.org/10.1155/2017/2505172

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors' Contributions

Lianyong Chen and Yu Pang contributed equally to this paper.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81560544). The authors are grateful to all staff from six prefectural TB dispensaries for their excellent work in sputum collection. They also would like to thank the members from National Tuberculosis Reference Laboratory for their technical assistance.

References

[1] V. Lisdawati, N. Puspandari, L. Rif'ati et al., "Molecular epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis drugs in Indonesia," BMC Infectious Diseases, vol. 15, no. 1, article 366, 2015.

[2] World Health Organization, Global Tuberculosis Report 2015, World Health Organization, Geneva, Switzerland, 2015.

[3] L. Wang, H. Zhang, Y. Ruan et al., "Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data," The Lancet, vol. 383, no. 9934, pp. 2057-2064, 2014.

[4] Y. Pang, Y. Zhou, B. Zhao et al., "Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China," PLoS ONE, vol. 7, no. 3, Article ID e32976, 2012.

[5] D. Zhang, J. An, J. Wang et al., "Molecular typing and drug susceptibility of Mycobacterium tuberculosis isolates from Chongqing Municipality, China," Infection, Genetics and Evolution, vol. 13, no. 1, pp. 310-316, 2013.

[6] Z. Zhang, J. Lu, M. Liu et al., "Genotyping and molecular characteristics of multidrug-resistant Mycobacterium tuberculosis isolates from China," Journal of Infection, vol. 70, no. 4, pp. 335-345, 2015.

[7] J. Singh, M. M. Sankar, P. Kumar et al., "Genetic diversity and drug susceptibility profile of Mycobacterium tuberculosis isolated from different regions of India," Journal of Infection, vol. 71, no. 2, pp. 207-219, 2015.

[8] C. L. Nogueira, R. I. Prim, S. G. Senna et al., "First insight into the molecular epidemiology of Mycobacterium tuberculosis in Santa Catarina, southern Brazil," Tuberculosis, vol. 97, pp. 57-64, 2016.

[9] World Health Organization, Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report, World Health Organization, Geneva, Switzerland, 2008.

[10] C. Demay, B. Liens, T. Burguiere et al., "SITVITWEB--a publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology," Infection, Genetics and Evolution, vol. 12, no. 4, pp. 755-766, 2012.

[11] T. Luo, C. Yang, Y. Pang, Y. Zhao, J. Mei, and Q. Gao, "Development of a hierarchical variable-number tandem repeat typing scheme for Mycobacterium tuberculosis in china," PLoS ONE, vol. 9, no. 2, Article ID e89726, 2014.

[12] P. R. Hunter and M. A. Gaston, "Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity," Journal of Clinical Microbiology, vol. 26, no. 11, pp. 2465-2466, 1988.

[13] I. Mokrousov, O. Narvskaya, E. Limeschenko, A. Vyazovaya, T. Otten, and B. Vyshnevskiy, "Analysis of the allelic diversity of the mycobacterial interspersed repetitive units in Mycobacterium tuberculosis strains of the Beijing family: practical implications and evolutionary considerations," Journal of Clinical Microbiology, vol. 42, no. 6, pp. 2438-2444, 2004.

[14] Q.-F. Liang, Y. Pang, Q.-Y. Chen et al., "Genetic profile of tuberculosis among the migrant population in Fujian Province, China," International Journal of Tuberculosis and Lung Disease, vol. 17, no. 5, pp. 655-661, 2013.

[15] R. Lan, C. Yang, L. Lan et al., "Mycobacterium tuberculosis and non-tuberculous mycobacteria isolates from HIV-infected patients in Guangxi, China," International Journal of Tuberculosis and Lung Disease, vol. 15, no. 12, pp. 1669-1674, 2011.

[16] Q. Liu, D. Yang, W. Xu et al., "Molecular typing of mycobacterium tuberculosis isolates circulating in Jiangsu Province, China," BMC Infectious Diseases, vol. 11, article 288, 2011.

[17] J. Wang, Y. Liu, C.-L. Zhang et al., "Genotypes and characteristics of clustering and drug susceptibility of Mycobacterium tuberculosis isolates collected in Heilongjiang Province, China," Journal of Clinical Microbiology, vol. 49, no. 4, pp. 1354-1362, 2011.

[18] Y. Liu, M. Tian, X. Wang et al., "Genotypic diversity analysis of mycobacterium tuberculosis strains collected from beijing in 2009, using spoligotyping and VNTR typing," PLoS ONE, vol. 9, no. 9, Article ID e106787, 2014.

[19] H. Dong, L. Shi, X. Zhao et al., "Genetic diversity of Mycobacterium tuberculosis isolates from Tibetans in Tibet, China," PLoS ONE, vol. 7, no. 3, Article ID e33904, 2012.

[20] T. Luo, I. Comas, D. Luo et al., "Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese," Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 26, pp. 8136-8141, 2015.

[21] T. N. Buu, M. N. Huyen, N. T. N. Lan et al., "The Beijing genotype is associated with young age and multidrug-resistant tuberculosis in rural Vietnam," International Journal of Tuberculosis and Lung Disease, vol. 13, no. 7, pp. 900-906, 2009.

[22] S. Phyu, R. Stavrum, T. Lwin, 0. S. Svendsen, T. Ti, and H. M. Grewal, "Predominance of Mycobacterium tuberculosis EAI and Beijing lineages in Yangon, Myanmar," Journal of Clinical Microbiology, vol. 47, no. 2, pp. 335-344, 2009.

[23] Y. Pang, Y. Song, H. Xia, Y. Zhou, B. Zhao, and Y. Zhao, "Risk factors and clinical phenotypes of Beijing genotype strains in tuberculosis patients in China," BMC Infectious Diseases, vol. 12, article 354, 2012.

[24] D. D. Anh, M. W. Borgdorff, L. N. Van et al., "Mycobacterium tuberculosis Beijing genotype emerging in vietnam," Emerging Infectious Diseases, vol. 6, no. 3, pp. 302-305, 2000.

[25] J. Wallinga, P. Teunis, and M. Kretzschmar, "Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents," American Journal of Epidemiology, vol. 164, no. 10, pp. 936-944, 2006.

[26] C. Yang, X. Shen, Y. Peng et al., "Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study," Clinical Infectious Diseases, vol. 61, no. 2, pp. 219-227, 2015.

[27] Y. Pang, W. Kang, A. Zhao et al., "The effect of bacille Calmette-Guerin vaccination at birth on immune response in China," Vaccine, vol. 33, no. 1, pp. 209-213, 2015.

[28] F. Abebe and G. Bjune, "The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guerin (BCG) vaccines: is there a link?" Clinical and Experimental Immunology, vol. 145, no. 3, pp. 389-397, 2006.

[29] A. G. Tsolaki, S. Gagneux, A. S. Pym et al., "Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis," Journal of Clinical Microbiology, vol. 43, no. 7, pp. 3185-3191, 2005.

[30] P. W. Smit, T. Vasankari, H. Aaltonen et al., "Enhanced tuberculosis outbreak investigation using whole genome sequencing and IGRA," European Respiratory Journal, vol. 45, no. 1, pp. 276-279, 2015.

[31] J. L. Gardy, J. C. Johnston, S. J. Ho Sui et al., "Whole-genome sequencing and social-network analysis of a tuberculosis outbreak," New England Journal of Medicine, vol. 364, no. 8, pp. 730-739, 2011.

Lianyong Chen, (1,2) Yu Pang, (3) Li Ma, (1,2) Huijuan Yang, (1,2) Haohao Ru, (1,2) Xing Yang, (1,2) Shuangqun Yan, (1,2) Mao Jia, (1,2) and Lin Xu (1,2)

(1) Yunnan Provincial Center for Tuberculosis Research, Yunnan Provincial Center for Disease Control and Prevention, Kunming, China

(2) Yunnan Provincial Dispensary for Tuberculosis Control and Prevention, Yunnan Provincial Center for Disease Control and Prevention, Kunming, China

(3) National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Institute, Capital Medical University, Beijing, China

Correspondence should be addressed to Lin Xu; 123316859@qq.com

Received 13 December 2016; Accepted 9 March 2017; Published 17 May 2017

Academic Editor: Isabel Portugal

Caption: FIGURE 1: Distribution of Beijing genotype MTB isolates enrolled in this study. The number presents the absolute number of isolates in this region.

Caption: FIGURE 2: Dendrogram of 271 MTB isolates from Yunnan Province. The phylogenetic tree was generated with the 12-VNTR loci set.
TABLE 1: Differences of characteristics between Han and minority
population.

                                     Number (%) of isolates

Characteristics   Total number of      Han        Minority
                     isolates        (n= 133)     (n= 138)

Resistance to

  INH                14 (5.2)         9 (6.8)      5 (3.6)
  RIF                 5 (1.8)         5 (3.8)      0 (0.0)
  MDR                 4 (1.5)         4 (3.0)      0 (0.0)

Gender

  Men               196 (72.3)       94 (70.7)   102 (73.9)
  Women              75 (27.7)       39 (29.3)    36 (26.1)

Age group (years)

  <25                44 (16.2)       21 (15.8)    23 (16.7)
  25-44             108 (39.9)       54 (40.6)    54 (39.1)
 45-64               92 (33.9)       45 (33.8)    47 (34.1)
  >64                27 (10.0)       13 (9.8)     14 (10.1)

Occupation

  Farmer            226 (83.4)      104 (78.2)   122 (88.4)
  Others             45 (16.6)       29 (21.8)    16 (11.6)

Region

  Qujing             49 (18.1)       48 (36.1)     1 (0.7)
  Dehong             35 (12.9)       13 (9.8)     22 (15.9)
  Lijiang            22 (8.1)         8 (6.0)     14 (10.1)
  Lincang            31 (11.4)       25 (18.8)     6 (4.3)
  Puer               94 (34.7)       27 (20.3)    67 (48.6)
  Xishuangbanna      40 (14.8)       12 (9.0)     28 (20.3)

Treatment History

  New case          246 (90.8)      120 (90.2)   126 (91.3)
  Retreated          25 (9.2)        13 (9.8)     12 (8.7)

Characteristics       OR        95% CI     P value

Resistance to

  INH                0.52      0.17~1.59    0.24
  RIF                0.96      0.93~0.99    0.03
  MDR                0.97      0.94~1.00    0.06

Gender

  Men             1.0 (Ref.)      --         --
  Women              1.18      0.69~2.00    0.55

Age group (years)

  <25             1.0 (Ref.)      --         --
  25-44              1.10      0.54~2.21    0.80
 45-64               1.05      0.51~2.15    0.90
  >64                1.02      0.39~2.65    0.97

Occupation

  Farmer             0.47      0.24~0.91    0.02
  Others          1.0 (Ref.)      --         --

Region

  Qujing          1.0 (Ref.)      --         --
  Dehong             0.01      0.00~0.10    <0.01
  Lijiang            0.01      0.00~0.10    <0.01
  Lincang            0.09      0.10~0.76    0.01
  Puer               0.01      0.00~0.07    <0.01
  Xishuangbanna      0.01      0.00~0.07    <0.01

Treatment History

  New case        1.0 (Ref.)      --         --
  Retreated          1.14      0.50~2.59    0.76

TABLE 2: Spoligotypes of the 271M. tuberculosis isolates enrolled
in this study.

SIT (a)   Lineage (b)   Number (%)

1           Beijing     136 (50.2)
190         Beijing      6 (2.2)
269         Beijing      3 (1.1)
1674        Beijing      2 (0.7)
632         Beijing      1 (0.4)
265         Beijing      1 (0.4)
743         Beijing      2 (0.7)
53            T1        35 (12.9)
7             T1         2 (0.7)
86            T1         1 (0.4)
120           T1         1 (0.4)
154           T1         1 (0.4)
205           T1         1 (0.4)
373           T1         1 (0.4)
1105          T1         1 (0.4)
1166          T1         1 (0.4)
2170          T1         1 (0.4)
52            T2         2 (0.7)
848           T2         1 (0.4)
1797          T2         1 (0.4)
1890          T2         1 (0.4)
73           T2-T3       4 (1.5)
37            T3        34 (12.5)
44            T5         1 (0.4)
183           H3         1 (0.4)
42           LAM9        1 (0.4)
249          LAM9        5 (1.8)
583          MANU2       2 (0.7)
137           X2         1 (0.4)
Orphan        NA         5 (1.8)
Orphan        NA         4 (1.5)
Orphan        NA         3 (1.1)
Orphan        NA         2 (0.7)
Orphan        NA         1 (0.4)
Orphan        NA         1 (0.4)
Orphan        NA         1 (0.4)
Orphan        NA         1 (0.4)
Orphan        NA         1 (0.4)
Orphan        NA         1 (0.4)
Orphan        NA         1 (0.4)

SIT (a)          Spoligotype description binary

1         xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx*********
190       xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx*****x***
269       xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx*******
1674      xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx*******x*
632       xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx***x*****
265       xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx**x******
743       xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx*****x*x*
53        ********************************xxxx*******
7         x*******************************xxxx*******
86        *********************x**********xxxx*******
120       *******************x************xxxx*******
154       ****x***************************xxxx*******
205       ***x****************************xxxx*******
373       ***********************x********xxxx*******
1105      ***************x****************xxxx*x*****
1166      ********************************xxxx***x***
2170      ***x****************************xxxx***x***
52        *****************************x**xxxx***x***
848       **********************xxx*******xxxx***x***
1797      ************x*******************xxxx***x***
1890      ************x*******************xxxx*******
73        ***********************x********xxxx*******
37        *******************x**********x*xxxx*******
44        *********************xxxx*******xxxx*******
183       ***********x*xxxxxxxxxxx********xxxx*******
42        *************x******************xx*********
249       *****************x**************xxxx**xxxx*
583       xxxxxxxxxxxxxxxxxxxxxxxx********xxxx*******
137       ****x******************xx*******xxxx*******
Orphan    ******x**********************xxxxxxxxxx****
Orphan    ************x**************x*x**xxxx*******
Orphan    ****x*******x*******************xxxx*******
Orphan    *****x******x*******************xxxx*******
Orphan    ****x***************************xxxx*****xx
Orphan    ********************************xxxxxx*x***
Orphan    *************x*******xx***xxxx**xxxx*******
Orphan    ***x****************xx**********xxxx*******
Orphan    *************x*******xx***xxxx**xxxx*******
Orphan    *************x********xx********xxxx*******
Orphan    *************x********xx********xxxx*******

(a) SIT from SITVITWEB database.

(b) Representing spoligotype lineages annotated in SITVITWEB database.

Number of strains with the same SIT.

Orphan represents the spoligotyping type which is not found in
SITVITWEB database.

TABLE 3: Differences of characteristics between Beijing and
non-Beijing genotype.

                                  Number (%) of isolates

Characteristics   Total number    Beijing     Non-Beijing
                  of isolates     (n= 151)     (n = 120)

Resistance to

  INH               14 (5.2)      8 (5.3)       6 (5.0)
  RIF               5 (1.8)       4 (2.6)       1 (0.8)
  MDR               4 (1.5)       3 (2.0)       1 (0.8)

Gender

  Men              196 (72.3)    100 (66.2)    96 (80.0)
 Women              75 (277)     51 (33.8)     24 (20.0)

Age group (years)

  <25              44 (16.2)     32 (21.2)     12 (10.0)
  25-44            108 (39.9)    65 (43.0)     43 (35.8)
  45-64            92 (33.9)     41 (27.2)     51 (42.5)
                   27 (10.0)      13 (8.6)     14 (11.7)

Occupation

  Farmer           226 (83.4)    121 (80.1)    105 (875)
  Others           45 (16.6)     30 (19.9)     15 (12.5)

Ethnicity

  Han              133 (49.1)    76 (50.3)     57 (47.5)
  Hani             30 (11.1)      11 (7.3)     19 (15.8)
  Yi               28 (10.3)      10 (6.6)     18 (15.0)
  Dai               26 (9.6)      13 (8.6)     13 (10.8)
  Others           54 (19.9)     41 (27.2)     13 (10.8)

Region

  Qujing           49 (18.1)     41 (27.2)      8 (6.7)
  Dehong           35 (12.9)     28 (18.5)      7 (5.8)
  Lijiang           22 (8.1)      12 (7.9)     10 (8.3)
  Lincang          31 (11.4)      10 (6.6)     21 (17.5)
  Puer             94 (34.7)     46 (30.5)     48 (40.0)
  Xishuangbanna    40 (14.8)      14 (9.3)     26 (21.7)

Treatment History

  New case         246 (90.8)    138 (91.4)   108 (90.0)
  Retreated         25 (9.2)      13 (8.6)     12 (10.0)

Characteristics       OR         95% CI     P value

Resistance to

  INH                0.94       0.32~2.79    0.91
  RIF                0.31       0.03~2.80    0.39
  MDR                0.41       0.04~4.04    0.63

Gender

  Men             1.00 (Ref.)      --         --
 Women               2.04       1.17~3.57    0.01

Age group (years)

  <25             1.00 (Ref.)      --         --
  25-44              0.57       0.26~1.22    0.14
  45-64              0.30       0.14~0.66    <0.01
                     0.35       0.13~0.95    0.04

Occupation

  Farmer             0.58       0.29~1.13    0.11
  Others          1.00 (Ref.)      --         --

Ethnicity

  Han             1.00 (Ref.)      --         --
  Hani               0.43       0.19~0.98    0.04
  Yi                 0.42       0.18~0.97    0.04
  Dai                0.75       0.32~1.74    0.50
  Others             2.37       1.16~4.82    0.02

Region

  Qujing          1.00 (Ref.)      --         --
  Dehong             0.78       0.25~2.40    0.67
  Lijiang            0.23       0.08~0.72    0.01
  Lincang            0.09       0.03~0.27    <0.01
  Puer               0.19       0.08~0.44    <0.01
  Xishuangbanna      0.11       0.04~0.28    <0.01

Treatment History

  New case        1.00 (Ref.)      --         --
  Retreated          0.85       0.37~1.93    0.69

Table 4: Allelic diversity of 12 different VNTR loci among
Mycobacterium tuberculosis strains (n = 271).

Locus                    HGDI
          All strains   Beijing   Non-Beijing

Qubllb       0.830       0.731       0.714
Qub18        0.854       0.813       0.672
Qub26        0.800       0.632       0.907
MIRU26       0.799       0.655       0.832
Mtub21       0.790       0.705       0.469
Mtub04       0.647       0.397       0.604
ETR-F        0.633       0.451       0.507
MIRU31       0.630       0.277       0.334
MIRU10       0.570       0.162       0.274
Qub4156      0.533       0.625       0.228
MIRU40       0.476       0.243       0.639
Qub1895      0.363       0.368       0.356
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Chen, Lianyong; Pang, Yu; Ma, Li; Yang, Huijuan; Ru, Haohao; Yang, Xing; Yan, Shuangqun; Jia, Mao; X
Publication:BioMed Research International
Article Type:Report
Geographic Code:9CHIN
Date:Jan 1, 2017
Words:5410
Previous Article:Application of Pneumatic Lithotripter and Holmium Laser in the Treatment of Ureteral Stones and Kidney Stones in Children.
Next Article:Brain Computer Interface Systems for Neurorobotics: Methods and Applications.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters